| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
353.27(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Papadopoulos Stelios |
|
– • – |
2024-03-14 |
4 |
A |
$1.60 |
$400,000 |
D/D |
250,000 |
978,388 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2024-01-18 |
4 |
AS |
$1.19 |
$6,510 |
D/D |
(5,468) |
10,056 |
|
98% |
|
| Hagan Joseph P |
Chief Executive Officer |
• • – |
2024-01-18 |
4 |
AS |
$1.19 |
$17,359 |
D/D |
(14,580) |
57,112 |
|
98% |
|
| Calsada Crispina |
Chief Financial Officer |
• – – |
2024-01-18 |
4 |
S |
$1.19 |
$6,510 |
D/D |
(5,468) |
5,782 |
|
-86% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2024-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
11,250 |
15,524 |
|
- |
|
| Hagan Joseph P |
Chief Executive Officer |
• • – |
2024-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
71,692 |
|
- |
|
| Calsada Crispina |
Chief Financial Officer |
• – – |
2024-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
11,250 |
11,250 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2023-04-13 |
4 |
A |
$0.90 |
$200,000 |
D/D |
222,198 |
728,388 |
|
- |
|
| Drygin Denis |
Chief Scientific Officer |
• – – |
2022-03-01 |
4 |
B |
$0.23 |
$17,638 |
D/D |
76,686 |
100,000 |
2.74 |
-2% |
|
| Drygin Denis |
Chief Scientific Officer |
• – – |
2022-02-04 |
4 |
B |
$0.23 |
$5,362 |
D/D |
23,314 |
23,314 |
2.74 |
4% |
|
| Hagan Joseph P |
President and CEO |
• • – |
2022-01-26 |
4 |
B |
$0.22 |
$21,520 |
D/D |
100,000 |
417,006 |
2.81 |
27% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2021-05-17 |
4 |
AS |
$0.89 |
$765 |
D/D |
(860) |
41,754 |
|
-18% |
|
| Hagan Joseph P |
President and CEO |
• • – |
2021-05-17 |
4 |
AS |
$0.89 |
$3,726 |
D/D |
(4,186) |
316,292 |
|
-18% |
|
| Hagan Joseph P |
President and CEO |
• • – |
2021-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
75,850 |
320,478 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2021-02-16 |
4/A |
AS |
$1.72 |
$7,128 |
D/D |
(4,144) |
244,628 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2021-02-16 |
4 |
AS |
$1.72 |
$7,128 |
D/D |
(4,144) |
485,756 |
|
-53% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2021-02-16 |
4 |
AS |
$1.72 |
$1,424 |
D/D |
(828) |
42,614 |
|
-53% |
|
| Papadopoulos Stelios |
Director |
– • – |
2020-12-04 |
4/A |
A |
$0.63 |
$500,002 |
D/D |
793,528 |
2,839,707 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2020-12-04 |
4 |
A |
$0.63 |
$25,002 |
I/I |
39,680 |
225,674 |
|
- |
|
| Behbahani Ali |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Walker Paul Edward |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Chang Carmen |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Sandell Scott D |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Florence Anthony A. Jr. |
10% Owner |
– – • |
2020-12-04 |
4 |
B |
$0.62 |
$2,735,930 |
I/I |
4,398,602 |
6,451,056 |
1.5 |
71% |
|
| Papadopoulos Stelios |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.63 |
$500,002 |
D/D |
793,528 |
1,986,729 |
|
- |
|
341 Records found
|
|
Page 1 of 14 |
|
|
0.15 (6.61%) 
